title: Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
abstract: The relationship between anti-topoisomerase-I antibodies and clinical findings was studied in 191 patients with definite systemic sclerosis. This was done by performing ELISA to detect antibodies to recombinant topoisomerase-I. Antibodies to topoisomerase-I were found in 72 patients (37%) with systemic sclerosis, which is a higher percentage than reported in most previous reports on a large unselected population. In 43 patients the presence of antibodies to recombinant topoisomerase-I was confirmed using both the immunodiffusion method and ELISA, with similar results. When classified into diffuse versus limited disease, a significant difference in antibody prevalence was demonstrated (P < 0.005), thus indicating that anti-topoisomerase-I antibody detection with ELISA may assist in early identification of systemic sclerosis subtypes.
authors: Department of Medicine B, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors: Y
authors: Y
authors: Shoenfeld
authors: E
authors: E
authors: Grunebaum
authors: M
authors: M
authors: Laufer
authors: N
authors: N
authors: Zurgil
authors: R
authors: R
authors: Bakimer
authors: A
authors: A
authors: Lunderschmidt
authors: G
authors: G
authors: Valentini
authors: G
authors: G
authors: Tirri
authors: M
authors: M
authors: Blank
mesh_terms: D001323:Autoantibodies / Q000097:blood*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D005779:Immunodiffusion; D015994:Incidence; D015995:Prevalence; D015203:Reproducibility of Results; D012595:Scleroderma, Systemic / Q000145:classification / Q000201:enzymology / Q000276:immunology*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D001323:Autoantibodies; D004264:DNA Topoisomerases, Type I